Antigen-specific T cells for the treatment of infections after transplantation

Hematology Journal

Volumn 4, Issue 1, 2003, Pages 10-17

  Einsele, Hermann ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Antigen specific T cells; Infection; Transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; OKT 3; THYMOCYTE ANTIBODY; FUNGUS ANTIGEN; HLA A2 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; VIRUS ANTIGEN;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; CLINICAL STUDY; CYTOMEGALOVIRUS; DNA MODIFICATION; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; SAFETY; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT INDICATION; VIRUS IMMUNITY; VIRUS INFECTION; ANIMAL; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDIASIS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALIC INCLUSION BODY DISEASE; GENE THERAPY; HUMAN ADENOVIRUS; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; MOUSE; POSTOPERATIVE COMPLICATION; T LYMPHOCYTE SUBPOPULATION; VIROLOGY;

ADENOVIRIDAE INFECTIONS; ADENOVIRUSES, HUMAN; ANIMALS; ANTIGENS, FUNGAL; ANTIGENS, VIRAL; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDIASIS; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; GENE THERAPY; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY, ADOPTIVE; LYMPHOPROLIFERATIVE DISORDERS; MICE; POSTOPERATIVE COMPLICATIONS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION; VIRUS DISEASES;

EID: 0037591400     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200213     Document Type: Review

References (61)

1. Meyers JD. Infections in marrow transplant recipients. In: Mandell GL, Douglas Jr RG, Bennett JE (eds.). Principles and Practices of Infectious Diseases. Churchill Livingstone: New York, 1990; pp 2291-2294.
2. Winston DJ. Prophylaxis and treatment of infection in the bone marrow transplant recipient. Curr Clin Top Infect Dis 1993; 13: 293-321.
3. Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70-75.
4. Hou S, Hyland L, Ryan KW, Portner A, Doherty PC. Virus-specific CD8+ T cell memory determined by clonal burst size. Nature 1994; 369: 652-654.
5. Mackenzie CD, Taylor PM, Askonas BA. Rapid recovery of lung histology correlates with clearance of influenza virus by specific CD8+ cytotoxic T cells. Immunology 1989; 67: 375-381.
6. Nash AA, Jayasuriya A, Phelan J, Cobbold SP, Waldmann H, Prospero T. Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J Gen Virol 1987; 68: 825-833.
7. Moskophidis D, Cobbold SP, Waldmann H, Lehmann-Grube F. Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response J Virol 1987; 61: 1867-1874.
8. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995; 13: 545-586.
9. Reddehase MJ, Mutter W, Munch K, Buhring HJ, Koszinowski UH. CD8-positive T lymphocytes specific for marine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 1987; 61: 3102-3108.
10. Reddehase MJ, Mutter W, Koszinowski UH. In vivo application of immune reconstitution strategies for prevention and recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med 1987; 165: 650-656.
11. Lucin P, Pavic I, Polic B, Jonjic S, Koszinowski UH. Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J Virol 1992; 66: 1977-1984.
12. Quinnan Jr GV, Kirmani N, Rock AH, Manischewitz JF, Jackson L, Moreschi G et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T lymphocyte and non-T lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982; 307: 7-13.
13. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373-1380.
14. Krause H, Hebart H, Jahn G, Muller CA, Einsele H. Screening for CMV specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19: 1111-1116.
15. Sester M, Sester U, Gartner B, Kubuschok B, Girndt M, Meyerhans A et al. Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol 2002; 76: 3748-3755.
16. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232-1240.
17. Aubert G, Hassan-Walker AF, Madrigal JA, Emery VC, Morte C, Grace S et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001; 184: 955-963.
18. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation [see comments]. N Engl J Med 1994; 330: 1185-1191.
19. Diamond DJ, York J, Sun JY, Wright CL, Forman SI. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997; 90: 1751-1767.
20. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones [see comments]. Science 1992; 257: 238-241.
21. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
22. Walter EA, Greenberg PD, Gilben MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
23. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treament of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916-3622.
24. Caldas C, Ambinder R. Epstein-Barr virus and bone marrow transplantation. Curr Opin Oncol 1995; 7: 102-106.
25. Martin PJ, Shulman HM, Schubach WH, Hansen JA, Fefer A, Miller G et al. Fatal Epstein-Barrvirus-associated proliferation of donor B cells alter treatment of acute graft-versus-host disease with a murine anti-T cell antibody. Ann Intern Med 1984; 101: 310-315.
26. Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C et al. Selective depletion of bone marrow T lymphocytes with anti-CDS monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139-2149.
27. Opelz G, Henderson R. Incidence of non-Hodgkin's lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516.
28. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991; 23: 1473-1476.
29. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL et al. Increased incidence of lymphoproliferative disorder alter immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728.
30. Basgoz N, Preiksaitis JK. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am 1995; 9: 901-923.
31. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM et al. Prettransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ trans-plantations. J Heart Lung Transplant 1995; 14: 214-221.
32. van Esser JW, Niesters HG, Thijsen SF, Meijer E, Osterhaus AD, Wolthers KC et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001; 113: 814-821.
33. Nolte A, Buhmann R, Straka C, Emmerich B, Hallek M. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 909-916.
34. Lucas KG, Schmall TN, Heller G, Dupont B, O'Reilly RJ. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87: 2594.
35. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157: 195-216.
36. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA et al. Use of gene-modified virusspecific T lymphocytes to control Epstein Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
37. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-555.
38. Gustafsson X, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients ar risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807-814.
39. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002, in press.
40. Kleihauer A, Grigoleit U, Hebart H, Moris A, Brossart P, Muhm A et al. Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Br J Hematol 2001; 113: 231-239.
41. Peggs K, Verfuerths S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001; 97: 994-1000.
42. Peggs K, Verfuerth S, Pizzey A, Ainsworth J, Moss P, Mackinnon S et al. Characterization of human cytomegalovirus peptide-specific CD8+ T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. Blood 2002; 99: 213-223.
43. Szmania S, Galloway A, Bruorton M et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 2001; 98: 505-512.
44. Bonini C, Lee SP, Riddell SR Greenberg PD. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 2001; 15: 5250-5257.
45. Keever-Taylor CA, Margolis D, Konings S, Sandford GR, Nicolette CA, Lawendowski C et al. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. Biol Blood Marrow Transplant 2001; 7: 247-256.
46. Hamel Y, Blake N, Gabrielsson S, Haigh T, Jooss K, Martinache C et al. Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy. Hum Gene Ther 2002; 13: 855-866.
47. Kondo E, Topp MS, Kiem HP, Obata Y, Morishima Y, Kuzushima K et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduces CD40-activated B cells. J Immunol 2002; 169: 2164-2171.
48. Savoldo B, Cubbage ML, Durett AG, Goss J, Huls MH, Liu Z et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol 2002; 168: 909-918.
49. Berencsi K, Gyulai Z, Gonczol E, Pincus S, Cox WI, Michelson S et al. A canarypox vector expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 2001; 183: 1171-1179.
50. Sester M, Sester U, Salvador SA, Heine G, Lipfert S, Girndt M et al. Age-related decrease in adenovirus-specific T cell responses. J Infect Dis 2002; 185: 1379-1387.
51. Grazziutti M, Przepiorka D, Rex JH, Braunschweig I, Vadhan-Raj S, Savary CA et al. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant 2001; 27: 647-652.
52. Bozza S, Gaziano R, Spreca A, Bacci A, Montagnoli C, di Francesco P et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol 2002; 168: 1362-1371.
53. Bacci A, Montagnoli C, Perruccio K, Bozza S, Gaziano R, Pitzurra L et al. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J Immunol 2002; 168: 2904-2913.
54. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
55. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA et al. T cell mediated rejection of gene-modified HIV specific cytotoxic T lymphocytes in HIV infected patients. Nat Med 1996; 2: 216-223.
56. Riddell SR, Greenberg PD, Overell RW, Loughran TP, Gilbert MJ, Lupton SD et al. Phase 1 study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum Gene Ther 1992; 3: 319-338.
57. Sauce D, Bodinier M, Garin M, Petracca B, Tonnelier N, Duperrier A et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 2002; 99: 1165-1173.
58. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000; 74: 8207-8212.
59. Kessels Hw, van den Boom MD, Spits H, Jhooijberg E, Schumacher TN. Changing T cell specificity by retroviral T cell receptor display. Proc Natl Acad Sci USA 2000; 97: 14578-14583.
60. Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin Inmmunol 2001; 98: 220-228.
61. Rossig G, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002; 99: 2009-2016.